全文获取类型
收费全文 | 3014篇 |
免费 | 134篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 59篇 |
儿科学 | 67篇 |
妇产科学 | 32篇 |
基础医学 | 605篇 |
口腔科学 | 158篇 |
临床医学 | 351篇 |
内科学 | 517篇 |
皮肤病学 | 119篇 |
神经病学 | 210篇 |
特种医学 | 119篇 |
外科学 | 347篇 |
综合类 | 29篇 |
预防医学 | 161篇 |
眼科学 | 62篇 |
药学 | 200篇 |
中国医学 | 4篇 |
肿瘤学 | 115篇 |
出版年
2022年 | 29篇 |
2021年 | 58篇 |
2020年 | 31篇 |
2019年 | 37篇 |
2018年 | 29篇 |
2017年 | 35篇 |
2016年 | 39篇 |
2015年 | 56篇 |
2014年 | 55篇 |
2013年 | 74篇 |
2012年 | 115篇 |
2011年 | 116篇 |
2010年 | 60篇 |
2009年 | 78篇 |
2008年 | 136篇 |
2007年 | 146篇 |
2006年 | 151篇 |
2005年 | 152篇 |
2004年 | 117篇 |
2003年 | 161篇 |
2002年 | 135篇 |
2001年 | 109篇 |
2000年 | 101篇 |
1999年 | 99篇 |
1998年 | 26篇 |
1997年 | 37篇 |
1996年 | 26篇 |
1995年 | 20篇 |
1993年 | 20篇 |
1992年 | 51篇 |
1991年 | 37篇 |
1990年 | 48篇 |
1989年 | 54篇 |
1988年 | 38篇 |
1987年 | 32篇 |
1986年 | 34篇 |
1985年 | 33篇 |
1984年 | 22篇 |
1979年 | 20篇 |
1976年 | 21篇 |
1974年 | 24篇 |
1973年 | 21篇 |
1972年 | 21篇 |
1970年 | 22篇 |
1885年 | 18篇 |
1880年 | 32篇 |
1879年 | 21篇 |
1877年 | 21篇 |
1876年 | 21篇 |
1875年 | 18篇 |
排序方式: 共有3155条查询结果,搜索用时 15 毫秒
991.
992.
993.
Postpartum anxiety is a condition of concern due to associated difficulties for the mother, her relationships, and her infant’s development. We revised one measure of postpartum anxiety symptoms, the Postpartum Worry Scale (PWS) to include items that tap concerns related to infant health and development, important potential domains of postpartum worry. This study presents the initial phase of validation for the PWS-R. An online sample of 1,231 mothers of infants ages birth to 24 months completed the PWS-R as well as a battery of measures. We conducted a split-sample confirmatory factor analysis (CFA) to assess the latent factor structure, and a series of models were tested to refine the measure. The newly constructed factors were correlated with theoretically similar measures to test the construct validity. Initial model testing revealed a four-factor structure (i.e., Relationships, Household, Time Allocations, and Health and Development) that included 13 items. Two-group CFA confirmed the latent factor structure. Theoretically similar measures correlated moderately with the newly created PWS-R factors. The psychometric findings for the PWS-R provide preliminary support for its use as a measure of postpartum worry. Next steps in the iterative validation process are considered. Recommendations for the PWS-R’s use in clinical and research contexts are discussed. 相似文献
994.
Engelhard D Cordonnier C Shaw PJ Parkalli T Guenther C Martino R Dekker AW Prentice HG Gustavsson A Nurnberger W Ljungman P;Infectious Disease Working Party of the European Bone Marrow Transplantation 《British journal of haematology》2002,117(2):444-450
Streptococcus pneumoniae (S. pneumoniae) may cause severe and lethal infections months and years following stem cell transplantation (SCT). In a prospective survey over a 3.5-year period, we assessed the incidence, risk factors and outcome for invasive pneumococcal infection (IPI) following SCT. Fifty-one episodes of IPI were reported: 43 episodes after bone marrow transplantation (BMT) and 8 after peripheral blood stem cell transplantation (PBSCT); 35 after allogeneic SCT and 16 after autologous SCT. Seven IPI episodes, all bacteraemias, were defined as early, occurring 1-35 d (median 3 d) post transplantation. Forty-four episodes were defined as late (> or = 100 d post SCT), occurring 4 months to 10 years (median 17 months) post transplantation. The incidences of early and late IPI were 2.03/1000 and 8.63/1000 transplantations respectively (P = 0.001). A higher incidence of late IPI was observed after BMT than after PBSCT (10.99 versus 3.23/1000; P < 0.01) and after allogeneic versus autologous SCT (12.20 versus 4.60/1000; P < 0.01). There was a higher estimated incidence of IPI in allogeneic patients with than in those without graft-versus-host disease (GVHD) (18.85 versus 8.25/1000; P = 0.015). The mortality rate was 20%, including 2/7 of early and 8/44 of late IPI. S. pneumoniae is a rare but important complication during the aplastic phase after SCT. In conclusion, S. pneumoniae is a significant cause of morbidity late post-transplantation, especially in allogeneic patients, and particularly those with GVHD. The high IPI mortality rate, both early and late post-transplantation, requires preventive approaches, mainly effective immunization. 相似文献
995.
Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study 总被引:3,自引:0,他引:3
Wenzel C Hussian D Bartsch R Pluschnig U Locker GJ Rudas M Gnant MF Jakesz R Zielinkski CC Steger GG 《Journal of cancer research and clinical oncology》2004,130(7):400-404
Purpose Combining anthracyclines and taxanes are to date the most active cytotoxic treatment option in the neoadjuvant and palliative therapy of breast cancer patients. Adding trastuzumab to these cytotoxic agents can improve outcome for women with human epidermal growth factor receptor 2 (HER2)-overexpressing advanced breast cancer. We conducted a pilot study of preoperative epidoxorubicin and docetaxel plus trastuzumab in outpatient patients suffering from breast cancer.Patients and methods Fourteen consecutive patients were enrolled in this prospective clinical pilot trial. Preoperative treatment consisted of weekly trastuzumab (4 mg/kg body-weight loading dose, 2 mg/kg/week maintenance dose), in combination with weekly epidoxorubicin (30 mg/m2 body surface area [BSA]) and docetaxel (35 mg/m2 BSA) once a week for 6 weeks followed by 1 week off therapy.Results Patients received a total of 30 cycles (median: 2 cycles, range: 2–3 cycles) of this therapeutic regimen. Outpatient epidoxorubicin and docetaxel plus trastuzumab were well tolerated. A major response to this preoperative therapy regimen could be demonstrated in 12 of 14 patients (86%) leading to breast-conserving surgery in 11 of 14 patients (79%).Conclusions We conclude that outpatient epidoxorubicin and docetaxel plus trastuzumab are safe in the neoadjuvant treatment of patients suffering from breast cancer, based on a favorable side-effect and activity profile. Thus, this regimen can be considered for further clinical trials.Work under the Auspices of CLEXO (Center of Excellence for Clinical and Experimental Oncology) 相似文献
996.
Nürnberger J Opazo Saez A Mitchell A Bührmann S Wenzel RR Siffert W Philipp T Schäfers RF 《Journal of human hypertension》2004,18(4):267-271
Arterial stiffening is the major cause of increasing systolic blood pressure in arterial hypertension. Increased arterial stiffness is one major mechanism responsible for morbidity and mortality in hypertension. A C825T polymorphism was identified in the gene encoding the G-protein beta3 subunit (GNB3), and an association of the T-allele with hypertension was demonstrated in several studies. In order to identify a pathogenetic link between hypertension and arterial stiffness, we compared two indices of arterial stiffness, pulse wave velocity (PWV) and augmentation index, in young, healthy men with and without the 825T-allele under resting conditions. PWV was determined from pressure tracing over carotid and femoral arteries in 99 subjects (CC: n=43; CT&TT: n=56). Augmentation index was derived in 72 subjects (CC: n=30; CT&TT: n=42) by pulse wave analysis using radial applanation tonometry. Carriers of the 825T-allele exhibited a significantly higher PWV compared to subjects with the CC genotype (6.0+/-0.1 m/s (TC&TT) vs 5.7+/-0.1 m/s (CC); P=0.0251). There was also a significant difference (P = 0.0448) in augmentation index between carriers of the T-allele (CT&TT: 3.4+/-2.9%) and controls with the CC -genotype (-5.0+/-4.1 %). There was no difference in any other anthropometric (age, height, weight, body mass index) or haemodynamic (heart rate, peripheral and central blood pressure). In summary, the C825T polymorphism is associated with higher arterial stiffness in young, healthy males. Arterial stiffening may pathogenetically contribute to the development of hypertension in carriers of the T-allele. 相似文献
997.
Trollmann R Strehl E Wenzel D Dörr HG 《The Journal of clinical endocrinology and metabolism》2000,85(8):2740-2743
GH deficiency (GHD) in patients with myelomeningocele leads to the question of whether these disabled patients should be treated with human GH. To date, only a few short-term reports of GH therapy are available in the literature, and long-term data for final height are lacking. We report auxological and laboratory data for seven prepubertal myelomeningocele patients with proven GHD (idiopathic GHD or neurosecretory dysfunction) during GH treatment. All patients (five males and two females; median chronological age, 6.6 yr) had shunted hydrocephalus and were treated with GH (0.5 IU/kg x week; 0.15 mg/kg x week; daily sc injections) over a median period of 38 months (range, 35-49 months). GH secretion was analyzed by measurement of spontaneous overnight GH secretion and two standard stimulation tests. Auxological parameters, bone age, serum levels of insulin-like growth factor I and insulin-like growth factor-binding protein-3, and neurological and orthopedic status were documented regularly. Median growth velocity of supine length improved during treatment (at start, 3.7 cm/yr; after 36 months, 5.7 cm/yr; P < 0.05), with highest levels 6 months after the start of therapy (8.1 cm/yr). The growth velocity of arm span was greater than these values. Supine length SD score for chronological age increased from -4.71 (at start) to -3.35 (after 36 months; P = NS), length SD score for bone age increased from -2.70 to -2.23 (P = NS), and arm span SD score increased from -2.98 to -1.75 (P < 0.05). The growth velocities of length and arm span remained significantly above the pretreatment values (P < 0.05). Symptomatic tethered cord associated with progression of scoliosis developed in two of seven children. GH treatment significantly improved the growth velocities of body length and arm span. However, the increase in length SD score was not significant, whereas arm span SD scores significantly improved over the study period. 相似文献
998.
Objective: Asthma is a common chronic disease with various phenotypes and therapeutic responses. Unlike other diseases, current anti-inflammatory treatment with corticosteroids does not include any reference to biological measures which may vary among different asthma phenotypes. Morbidity from uncontrolled asthma suggests a need for specific targeted treatment approaches such as biologic medications. In half of asthmatics, chronic airway inflammation may be driven by T helper (Th)-2 cells, which release pro-inflammatory cytokines, such as interleukin (IL)-4, IL-5 and IL-13, contributing to eosinophil inflammation and IgE production. Earlier studies of cytokine-targeted biologic therapy on non-phenotyped asthma patients were generally not clinically effective. Methods: Literature published from 1958–2013 was identified through PubMed using the search terms which included asthma and therapy. A total of 32 studies were reviewed covering both pediatric and adult asthmatics and included double-blind randomized placebo-controlled trials testing efficacy of biologic agents to treat asthma. Results: More recent approaches to personalized medicine with expression profiling studies, genetic analysis and clinical biomarkers of Th2 inflammation have allowed identification of asthma phenotypes including a Th2 “high” phenotype. Studies targeting IgE, IL-5, IL-13 and the IL4 receptor alpha chain have shown some efficacy in phenotyped patients. For those without evidence of Th2 inflammation, no specific therapies have been identified. Conclusions: In recent years, the identification of Type-2 cytokine “high” asthma in numerous studies has predicted the clinical response to the Th2 associated therapies. It is not yet clear whether all Type 2 high asthma will respond similarly to IL-4, 5 and 13 approaches. 相似文献
999.
Rubens Spin-Neto Louise Hauge Matzen Louise Hermann Joo Marcus de Carvalho e Silva Fuglsig Ann Wenzel 《Dento maxillo facial radiology》2021,50(3)
Objectives:To assess the frequency and characteristics (number, complexity, and distance) of head movements, and the perception of discomfort during simulated CBCT examinations in children, considering units with different patient positioning method and head immobilization device combinations.Methods:Forty children (20 boys/20 girls, age range 10–14 years) were video-recorded during simulated CBCT examinations. Children were randomly allocated to a sequence of five CBCT units: Newtom-5G, Orthophos-SL, Cranex-3Dx (patient standing/sitting), and X1. The child scored his/her discomfort perception (visual scale) and the preferred/ill-favored unit. Three observers scored the videos (20% in duplicate): child movement (yes/no), number (<3/≥3/continuous), complexity (uniplanar/multiplanar) and distance (<3 mm/≥3 mm). κ statistics provided intra-/interobserver reproducibility. Severe/extreme motion was defined based on movement characteristics. Chi-square tests assessed the frequency differences of severe/extreme motion among the units, age and operator. Logistic regression analyses with severe/extreme motion as outcome were performed.Results:The range of intra- and inter-observer reproducibility for movement observation was 0.78–0.89 and 0.61–0.64, respectively. Between 60% (Newtom-5G) and 100% (X1) of children moved during the examination. Severe/extreme motion was significantly related to unit and age. There was significantly less severe/extreme motion, when the child was in the supine position with a foam headrest as head support. The younger the child, the higher the risk for severe/extreme motion. The majority of the children preferred the unit with the supine position and a foam headrest.Conclusions:The prevalence of severe and extreme motion was associated with the unit’s patient positioning method and head immobilization devices combined, and child age. 相似文献